Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | CTPS1 | P17812 | 3/20 | 0.46 |
| ▸ | SGK1 | O00141 | 1/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 4/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375807 | 0.84 | DHODH (0.55) | CTPS1PTGES2PIM1ABL1SLC22A12 | |
| SCHEMBL3379953 | 0.82 | KIF11 (0.74) | KIF11PTGES2ABL1 | |
| SCHEMBL3379334 | 0.75 | KIF11 (0.46) | KIF11ABL1IDH1MAP2K4DHODH | |
| SCHEMBL3374882 | 0.74 | PGR (0.55) | SGK1UCHL1USP30 | |
| SCHEMBL3375684 | 0.73 | ACLY (0.43) | KIF11CTPS1PTGES2 | |
| SCHEMBL5840598 | 0.71 | SLC13A5 (0.51) | KIF11PTGES2DHODH | |
| SCHEMBL1044062 | 0.69 | CYP1A2 (0.51) | PTGES2DHODH | |
| SCHEMBL5544749 | 0.69 | SLC13A5 (0.47) | PTGES2DHODH | |
| SCHEMBL1337217 | 0.69 | TAAR1 (0.52) | KIF11PTGES2DHODH | |
| SCHEMBL5379608 | 0.69 | ESR1 (0.55) | PIM1ABL1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | claimed |
| WO-2010056527-A2 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-20 | — | — | WO | claimed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389500-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113449-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, HCN4, KCNH2 | KIF11 3561/4885CTPS1 2247/4885SGK1 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.